Dr. Atsushi Hayashi, Director of SBC Medical-Supported Shonan Aesthetic Dermatology Gotanda, Presents Research Findings at AMSC Malaysia 2026
Dr. Hayashi presented clinical approaches to injectable treatment for under-eye hollowing and eye bags at an international aesthetic medicine conference in Kuala Lumpur
IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Dr. Atsushi Hayashi, Director of Shonan Aesthetic Dermatology Gotanda, a clinic that receives management support from the Company, presented research findings at AMSC Malaysia 2026, held in Kuala Lumpur, Malaysia, on August 13 and 14, 2026.
The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) is an international conference that brings together specialists in aesthetic dermatology and aesthetic surgery, along with other healthcare professionals from across the field, to share advanced knowledge and techniques. Now in its fifth edition, AMSC Malaysia 2026 was held over two days at the Kuala Lumpur Convention Centre (KLCC), with a program of case studies, scientific sessions, and industry updates delivered by local and international speakers. The conference is also recognized as an occasion for specialists from different countries to deepen their expertise and build international professional networks.
At the conference, Dr. Hayashi delivered a presentation titled “Treatment Of Tear Trough Depressions And Eye Bags Using Injectables.” Drawing on his clinical experience, he discussed specialized approaches to under-eye rejuvenation using injectable treatments, including hyaluronic acid, and shared clinical findings with an audience of specialists from around the world.
As technological innovation continues to accelerate in the field of aesthetic healthcare, the importance of knowledge sharing and academic collaboration, beyond the clinical setting alone, has grown considerably. Meeting the increasingly diverse needs of customers requires not only the adoption of advanced techniques, but also broad perspectives and flexible thinking. SBC Medical remains committed to advancing cutting-edge initiatives through academic presentations and research collaborations with institutions overseas, and to upholding the safety, transparency, and enduring value of aesthetic healthcare.
Overview of AMSC Malaysia 2026
Venue: Kuala Lumpur Convention Centre (KLCC), Kuala Lumpur, Malaysia
Dates: August 13 (Thu) and 14 (Fri), 2026
Official website: https://www.amsc.com.my
Presentation Title
Dr. Atsushi Hayashi (Director, Shonan Aesthetic Dermatology Gotanda)
“Treatment Of Tear Trough Depressions And Eye Bags Using Injectables”
About Dr. Atsushi Hayashi
Dr. Hayashi is Director of Shonan Aesthetic Dermatology Gotanda. Focusing on minimally invasive care, including injectable treatments, he designs specialized and comprehensive treatment plans based on each customer’s condition and overall facial balance. Taking a long-term view, he works alongside customers as concerns change with age, offering support that extends from combining procedures and planning treatment schedules to aging care with the years ahead in mind. Through aesthetic healthcare, he aims to help customers go about their days feeling brighter and more positive.
About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp